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Pseudomonas aeruginosa possesses a type III secretion system (T3SS) to intoxicate host
cells and evade innate immunity. This virulence-related machinery consists of a molecular
syringe and needle assembled on the bacterial surface, which allows delivery ofT3 effector
proteins into infected cells. To accomplish a one-step effector translocation, a tip protein
is required at the top end of the T3 needle structure. Strains lacking expression of the
functional tip protein fail to intoxicate host cells. P. aeruginosa encodes aT3S that is highly
homologous to the proteins encoded by Yersinia spp. The needle-tip proteins of Yersinia,
LcrV, and P. aeruginosa, PcrV, share 37% identity and 65% similarity. Other known tip pro-
teins are AcrV (Aeromonas), IpaD (Shigella), SipD (Salmonella), BipD (Burkholderia), EspA
(EPEC, EHEC), Bsp22 (Bordetella), with additional proteins identiﬁed from various Gram-
negative species, such as Vibrio and Bordetella. The tip proteins can serve as a protective
antigen or may be critical for sensing host cells and evading innate immune responses.
Recognition of the host microenvironment transcriptionally activates synthesis of T3SS
components. The machinery appears to be mechanically controlled by the assemblage of
speciﬁc junctions within the apparatus. These junctions include the tip and base of the T3
apparatus, the needle proteins and components within the bacterial cytoplasm.The tip pro-
teins likely have chaperone functions for translocon proteins, allowing the proper assembly
of translocation channels in the host membrane and completing vectorial delivery of effec-
tor proteins into the host cytoplasm. Multi-functional features of the needle-tip proteins
appear to be intricately controlled. In this review, we highlight the functional aspects and
complex controls of T3 needle-tip proteins with particular emphasis on PcrV and LcrV.
Keywords: type III secretion, needle-tip proteins, PcrV, LcrV, Pseudomonas aeruginosa,Yersinia, protective antigen
INTRODUCTION
The type III secretion system (T3SS) is likened to a molecular
machine located on the surface and within the envelope of many
Gram-negative bacteria. These systems are essential for virulence
and act as a syringe and needle, called an injectisome, forming a
channel in the eukaryotic membrane to facilitate the passage of
bacterial effectors into infected cells (Galan and Collmer, 1999;
Cornelis, 2006). The T3S apparatus has been identiﬁed in a vari-
ety of pathogens that infect animals, plants, and insects (Hueck,
1998;Mota andCornelis, 2005;Troisfontaines andCornelis, 2005).
Functional attributes of T3SS effectors vary among bacterial gen-
era, with cytotoxicity and anti-phagocytic activity being charac-
teristic for Pseudomonas aeruginosa and Yersinia spp., invasion,
intracellular survival, and the promotion of proinﬂammatory
responses for Shigella and Salmonella spp., and profound effects
on cytoskeletal structure for many other pathogens (reviewed in
Hueck, 1998; Galan and Collmer, 1999; Mota and Cornelis, 2005).
More than 20 T3S systems have been identiﬁed in 16S RNA
based studies (Cornelis, 2002; Troisfontaines and Cornelis, 2005).
In P. aeruginosa, 36 genes are involved in T3S (Frank, 1997). The
structure of the assembled injectisome is complex and several com-
ponents constitute the apparatus.An extracellular needle structure
topped with a tip complex extrudes from the basal body that
consists of multiple rings spanning the bacterial inner and outer
membranes (Figure 1). The inner and outer rings of the basal
body are connected by a neck domain. A T3S-associated ATPase,
another component of the basal body located at the cytosolic
face, is involved in the dissociation of secretion substrates from
their chaperones as well as supplying energy for protein export
(Figure 1; Cornelis, 2006; Galan and Wolf-Watz, 2006; Blocker
et al., 2008; Moraes et al., 2008; Mueller et al., 2008). Bacteria have
to complete the assembly of the basal body and polymerize the
needle subunit proteins to an appropriate length prior to the for-
mation of the tip complex on the distal end, which is controlled
by a substrate-switching mechanism (Journet et al., 2003; Galan
and Wolf-Watz, 2006). Other proteins necessary for a functional
T3SS are intracellular regulators, specialized chaperones, translo-
cators or translocases, and effectors (Cornelis, 2006; Galan and
Wolf-Watz, 2006; Schroeder and Hilbi, 2008; Hauser, 2009; Parsot,
2009).
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FIGURE 1 | Schematic diagram of the type III apparatus and host
membrane.TheT3SS injectisome comprises an extracellular needle
structure from the basal body that spans the bacterial inner and outer
membranes (indicated as IM and OM), the tip complex topped at the distal
end of the needle (shown in blue) and aT3S-associated ATPase located at
the cytosolic face of the basal body (shown in a rainbow color). The ATPase
is involved in the dissociation of unfolded substrates from the specialized
chaperones in addition to supplying energy for protein export (Galan and
Wolf-Watz, 2006). It is postulated that the structure and assembly of tip
complexes are distinct for each protein family: V-tip proteins form a
homo-pentamer complex, IpaD requires IpaB to assemble the
hetero-pentamer complex, and EC family proteins assemble into a
ﬁlamentous structure (Knutton et al., 1998; Veenendaal et al., 2007). The tip
complex is required for the assembly of a translocon (PopB and PopD for
Pseudomonas, YopB andYopD forYersinia) in the host cell membrane
(Cornelis, 2006; Hauser, 2009). An unfolded effector protein is transferred
through the channel of the needle and translocon and eventually delivered
into the host cytosolic compartment (blue ribbon).
Activation of the T3SS is postulated to occur upon sensing
the presence of host cells. Bacteria respond by turning on the
transcription of T3SS genes, inserting a translocation complex or
translocon assembled with translocator proteins into eukaryotic
membranes, and eventually delivering effector proteins into the
host to result in manipulation of cell physiology (Figure 1; Deane
et al., 2006; Veenendaal et al., 2007; Mueller et al., 2008; Hauser,
2009; Parsot, 2009). Structural and functional aspects of the T3SS
and related proteins have been summarized in numerous reviews,
thus this review focuses on the needle-tip proteins pertaining to
theYsc family,PcrV fromP. aeruginosa andLcrV fromYersinia spp.
The tip complex likely possesses multiple roles in T3SS-mediated
modulation of host cellular physiology: (1) sensing themicroenvi-
ronment of host cell membranes and propagating a signal back to
the bacterial cell, (2) regulation of secretion and translocation at
the level of the tip complex coordinated with transcriptional acti-
vation or repression of bacterial genes, (3) assembly and insertion
of a translocon in eukaryotic membranes, (4) physically bridging
the needle and translocon embedded in the hostmembrane during
effector delivery, and (5) serving as a clinically important protec-
tive antigen. In this review, we will discuss these multi-functional
properties of T3 needle-tip proteins.
NEEDLE-TIP COMPLEXES OF THE T3SS
FAMILIES OF TIP PROTEINS AND STRUCTURAL CONSIDERATIONS
In animal pathogens, there are three major classes of T3SS:
(1) the Ysc family that include the so-called V-tip proteins,
PcrV (P. aeruginosa), LcrV (Yersinia spp.), and AcrV from
a ﬁsh pathogen, Aeromonas salmonicida; (2) the Inv-Mxi-Spa
family members identiﬁed in Shigella ﬂexneri and Salmonella
typhimurium (belonging to the SPI-1 system), and (3) the Esc
family of enteropathogenic E. coli (EPEC), enterohemorrhagic E.
coli (EHEC), and S. typhimurium (SPI-2 system; Cornelis, 2002,
2006). In the Ysc family, PcrV and LcrV share the highest overall
homology (Table 1). Recently, another proteinVp1659 fromVibrio
parahaemolyticus was identiﬁed as a member of this family (Zhou
et al., 2010). The amino acid sequenceof theC-terminus ofVp1659
Table 1 | Needle-tip proteins of type III secretion system.
No. of
residues
Global alignmenta
with PcrV identity
(similarity)
GenBank
accession no.
V-tip protein (Ysc family)
PcrV Pseudomonas
aeruginosa
294 Strain PA103, ours
LcrV Yersinia spp. 326 36.4% (64.4%) P23994
AcrV Aeromonas
spp.
361 34.2% (59.8%) YP_001144289
Vp1659 Vibrio para-
haemolyti-
cus
607 35.3%b (55.7%b) NP_798038
Tip protein containing a chaperone domain (Inv-Mxi-Spa family)
IpaD Shigella
ﬂexneri
332 18.2% AAL72350
SipD Salmonella
spp.
343 20.4% ACY89896
BipD Burkholderia
pseudoma-
llei
310 21.6% EET03029
CT584 Chlamydia
trachomatis
183 16.4% NP_220099
Filamentous-tip protein (EC family)
EspA EPEC/EHECc 192 17.0% ACG59618
Bsp22 Bordetella
spp.
205 17.3% CAE32114
aAnalyzed by using ALIGN © 1997 by William R. Pearson and the University of
Virginia).
bResidues 420-607 of Vp1659 were used for alignment.
cEPEC: enteropathogenic E. coli; EHEC: enterohemorrhagic E. coli.
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(residues 420–607) is homologous to PcrV (residues 95–294) with
35% identity and 55% similarity (Table 1). The Inv-Mxi-Spa fam-
ily, is comprised of IpaD (S. ﬂexneri), SipD (Salmonella spp.),BipD
(Burkholderia pseudomallei), and CT584 (Chlamydia trachoma-
tis; Erskine et al., 2006; Espina et al., 2006; Johnson et al., 2007;
Lara-Tejero and Galan, 2009). Although the proteins in this fam-
ily contain less sequence identity to PcrV (Table 1), the structural
similarity of IpaD, BipD, and SipD to the V-proteins has been well
studied (Blocker et al., 2008; Mueller et al., 2008). CT584 is a late
cycle gene product of C. trachomatis (Betts-Hampikian and Fields,
2010) and the tertiary structure of this protein could be modeled
based on the structure of IpaD (Markham et al., 2009). Esc family
members include EspA (EPEC and EHEC) and Bsp22 (Bordetella
spp.; Table 1). These proteins polymerize and assemble into a dis-
tinct ﬁlamentous structure at the tip of the T3 needle (Knutton
et al., 1998; Daniell et al., 2001; Crepin et al., 2005; Medhekar
et al., 2009). Despite the little structural similarity to the other tip
protein families, the polymerized-tip complex appears to function
similarly in T3SS (Knutton et al., 1998; Crepin et al., 2005).
PcrV and LcrV tip proteins are located at the distal end of the
needle structure and required for the pathogenic phenotype of
host infection (Fields et al., 1999; Pettersson et al., 1999; Sato et al.,
2011). Bacterial strainswith adeletionof pcrV or lcrV are avirulent
inmice (Carter et al., 1980; Price et al., 1991; Skrzypek and Straley,
1995; Sawa et al., 1999) and during infection of cultured epithelial
or phagocytic cells (Pettersson et al., 1999; Sato et al., 2011). In cell
culture systems,pcrV -deletion strains release effector proteins into
the culturemedium and are incapable of vectorial translocation of
effectors into the host cytosol (Sawa et al., 1999; Goure et al., 2004;
Sato et al., 2011). Complementation with wild-type pcrV restores
translocation and cytotoxicity, suggesting the important role of
the tip protein in the intoxication of eukaryotic cells.
The crystal structure of LcrV revealed an overall dumb-
bell shape with a “grip” formed by the coiled-coil interaction
of two internal α-helices ﬂanked by globular domains at each
end (Derewenda et al., 2004). Other V-proteins have sufﬁcient
sequence similarity to construct structural models using LcrV as
a template (1r6f chain A, deposited in PBD; Derewenda et al.,
2004). The members of the Ysc family modeled by using the Swiss
Model server1 (Guex and Peitsch, 1997) are shown in Figure 2.
The coiled-coil structure of two long α-helices is conserved in all
three families of the tip proteins (Derewenda et al., 2004; Yip et al.,
2005; Johnson et al., 2007; Blocker et al., 2008;Mueller et al., 2008).
Current structural studies indicate that tip proteins form an
oligomer, possibly a pentamer, at the top end of the needle struc-
ture (Mueller et al., 2005, 2008; Deane et al., 2006; Broz et al., 2007;
Caroline et al., 2008). Scanning transmission electron microscopy
analyses visualized the oligomer structures of parental or chimeric
V-tip proteins on the assembled needle expressed in the lcrV
deletion strain of Y. enterocolitica (Mueller et al., 2005; Broz
et al., 2007). The N-terminal globular domain of LcrV, PcrV, and
AcrV form the base structure of the tip complex that interacts
with the YscF needle (Broz et al., 2007). PcrV forms a complex
with a narrower base than that of LcrV or AcrV (Mueller et al.,
1http://www.expasy.org
FIGURE 2 | Structural models of theV-tip protein family. V-tip proteins
are modeled using LcrV (PBD: 1r6f chain A) as a template (Swiss Model
server, http://www.expasy.org). The models indicate the conserved
coiled-coil structure of two α-helices ﬂanked by globular domains at each
end. One of the globular domains contains protective-epitope regions
identiﬁed in PcrV and LcrV (a while circle; Frank et al., 2002; Quenee et al.,
2010). The immunomodulatory region of LcrV (residues 271 to 300) is
located in one of the coiled-coil helices with a connected coil structure
(indicated in white; Overheim et al., 2005). This region is deleted in the rV10
subunit vaccine, by which the immunomodulatory responses are eliminated
(Overheim et al., 2005).
2005; Broz et al., 2007). Compared to LcrV translocons (YopB
and YopD), PcrV expressed in Y. pseudotuberculosis assembles
smaller translocation channels with YopB and YopD in infected
erythrocyte membranes and slowly delivers effector proteins into
host cells (Holmstrom et al., 2001; Broms et al., 2003). The
AcrV oligomerized structure is larger in size and varied in shape
(Mueller et al., 2005).
Structural studies of Inv-Mxi-Spa family members demon-
strate that the N-terminal domain of IpaD, SipD, and BipD pos-
sesses structural similarity to common chaperones, suggesting a
self-chaperoning function of the domain (Erskine et al., 2006;
Johnson et al., 2007; Blocker et al., 2008; Wang et al., 2010b;
Chatterjee et al., 2011; Rathinavelan et al., 2011). In contrast, the
N-terminal structure of V-proteins is predicted to be globular and
appears to have no intramolecular chaperoning domain (Blocker
et al., 2008). PcrV and LcrV utilize cognate chaperones PcrG and
LcrG in the bacterial cytoplasm. The chaperones and V-proteins
are expressed from genes located within the same operon (Blocker
et al., 2008; Lee et al., 2010). EspA is chaperoned by CesA (Yip
et al., 2005).
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The distinct coiled-coil structure in the center of the V-tip pro-
teins is similar to the coiled-coil formation of monomeric needle
proteins, such as MxiH from Shigella (Deane et al., 2006), sug-
gesting a common mechanism of assembly and interaction of tip
proteins and needle subunits (Blocker et al., 2008). One of the
coiled-coil helices in LcrV is structurally homologous to a sta-
bilizing helix of monomeric MxiH, which permits the modeling
of the LcrV tip complex on the top of the MxiH needle with-
out structural restraints (Deane et al., 2006). Also, it has been
shown that the lower part of the coiled-coil structure of SipD
interacts with the Salmonella needle protein PrgI (Rathinavelan
et al., 2011).
SENSING THE MICROENVIRONMENT AND HOST CELLS
Bacteriamodulate gene expression according to growth conditions
to maximize advantageous strategies for survival and contin-
ued replication. It has been suggested that as bacteria sense the
growth environment, the clusters of T3SS genes are transcription-
ally repressed or activated (reviewed in Motin et al., 1994; Hill
et al., 1997; Sawa et al., 1999; Brubaker, 2003; Yahr and Wolfgang,
2006; Brutinel and Yahr, 2008; Urbanowski and Yahr, 2008; Baer
et al., 2009). For P. aeruginosa, a low-calcium growth environ-
ment is one signal to derepress or induce T3SS transcription by
the exsCEBA-control system with an additional regulatory pro-
tein, ExsD (McCaw et al., 2002; Dasgupta et al., 2004; Rietsch
et al., 2005; Urbanowski et al., 2005, 2007; Brutinel et al., 2009).
Translocator and effector proteins are secreted into the extracel-
lular growth medium under low-calcium conditions (Yahr et al.,
1997). When calcium concentrations are sufﬁciently high, secre-
tion of effectors is inhibited (Frank, 1997;Yahr et al., 1997;McCaw
et al., 2002). In addition to calciumdepletion, other signals that are
involved in ExsA-mediated regulation of the T3SS include host–
cell contact, the contribution of two component system regulators,
DNA damage, and osmotic and metabolic stresses (Rietsch et al.,
2004;Rietsch andMekalanos,2006;Yahr andWolfgang,2006;Kang
et al., 2009). In Yersinia, LcrQ was identiﬁed as a transcriptional
regulator protein unique to Yersinia with no homolog found in
Pseudomonas (Wulff-Strobel et al., 2002). T3SS transcriptional
control in Yersinia also involves regulators, LcrH, SycH,YopD, and
YscM1/2 (Rimpilainen et al., 1992; Pettersson et al., 1996; Brutinel
and Yahr, 2008). In addition, the T3SS is regulated by changes in
oxygen levels or by intracellular pH as observed in cellular infec-
tions with EHEC, Shigella, or Salmonella (SPI-2; Marteyn et al.,
2010; Schuller and Phillips, 2010; Yu et al., 2010). Further, the
T3SS mRNA levels are post-transcriptionally modulated by small
RNAs (Bordi et al., 2010).
It is postulated that the T3 needle-tip complex functions as a
sensor of the growth environment and the presence of host cells for
infection (Deane et al., 2006;Veenendaal et al., 2007;Mueller et al.,
2008; Parsot, 2009). A physiological signal for T3SS activation is
the recognition of eukaryotic membranes upon contact (Menard
et al., 1994; Pettersson et al., 1996). Contact of a pathogen to the
host cell induces expression of T3SS proteins, leading to the polar-
ized transfer of effectors into the target cell cytosol (Menard et al.,
1994; Rosqvist et al., 1994; Cisz et al., 2008). Contact-mediated
inductionof ExoS expression requires host cell integrity (Cisz et al.,
2008). For S. ﬂexneri, interactionwith epithelial cells or incubation
with serum is required to release IpaB and IpaC proteins (Menard
et al., 1994).
Low-calcium conditions, induced by the addition of a calcium
chelater to the growth medium, activate the T3SS in Pseudomonas
and Yersinia (Carter et al., 1980; Frank et al., 1994). Mutations
in pcrV or lcrV lead to a calcium-insensitive phenotype (Carter
et al., 1980; Bergman et al., 1991; Sato et al., 2011). In the Shigella
T3SS, several inducers have been shown, such as the amphipathic
dye Congo Red, fetal bovine serum, cholesterol-containing lipids,
and bile salts (Bahrani et al., 1997; Blocker et al., 1999; van der
Goot et al., 2004; Olive et al., 2007). The Shigella tip protein IpaD
“senses”deoxycholate or other bile salts in the environment, result-
ing in a conformational change in IpaD and subsequent step-wise
activation of the secretion apparatus by recruitment of IpaB to the
tip (Stensrud et al., 2008; Dickenson et al., 2011). After completion
of IpaB surface presentation, followed by interaction with choles-
terol and sphingomyelin containing lipids, IpaCmoves toward the
surface of the needle tip (Epler et al., 2009). At this stage, the tip
complex is poised for translocation of effectors (Epler et al., 2009).
Salmonella SipD also interacts with bile salts (Wang et al., 2010b;
Chatterjee et al., 2011). InV. parahaemolyticus, a bile acidwas iden-
tiﬁed as a host-derived inducer for T3SS genes in a transcriptional
regulator-dependent manner, yet the involvement of tip proteins
is unknown (Gotoh et al., 2010).
REGULATION OF TYPE III SECRETION AND TRANSLOCATION
In this section, we describe the post-translational control of the
T3SS, which requires multiple levels of regulatory proteins and
several types of signals (Pettersson et al., 1996;Wulff-Strobel et al.,
2002; Agrain et al., 2005; Akeda and Galan, 2005; Galan andWolf-
Watz, 2006; Sorg et al., 2007; Botteaux et al., 2009). To complete the
formation of a translocon and delivery of effectors into host cells,
a functional injection apparatus, including the basal body, needle,
and tip complex,must be assembled. Thismultistep process is pos-
tulated to be accomplished by a substrate-switching mechanism,
a hierarchical and timely regulation of protein export, which will
be discussed later. Post-translational regulation is organized into
six classes based on the location of the regulatory or accessory
proteins.
(1) The needle-tip complex of the injectisome: The tip complex is
located at the distal end of the needle structure (Mueller et al.,
2005; Broz et al., 2007; Blocker et al., 2008). V-tip proteins
have been shown to be involved in the mechanical regulation
of translocation and secretion (Sarker et al., 1998; Sato et al.,
2011). Bacterial strains containing a deletion of a gene encod-
ing a tip protein, pcrV or ipaD, are non-cytotoxic and possess
a deregulated secretion phenotype as measured by the con-
stitutive secretion of effector proteins (Menard et al., 1993;
Frank, 1997; Sawa et al., 1999; McCaw et al., 2002; Goure
et al., 2004; Picking et al., 2005; Rietsch et al., 2005; Sato et al.,
2011). For pcrV and lcrV deletion strains, this is referred to
as a calcium-blind or calcium independent phenotype (Carter
et al., 1980;Bergman et al., 1991; Sato et al., 2011). Similarly, an
ipaD-deletionmutant is insensitive to the inducer, Congo Red
(Veenendaal et al., 2007). These data suggest that tip proteins
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are involved in the control of translocation and secretion of
effectors by the type III apparatus.
(2) The needle protein: It has been postulated that the type III
needle propagates signals between the needle-tip sensor and
regulators in the bacterial cytoplasm (Kenjale et al., 2005;
Torruellas et al., 2005; Deane et al., 2006). The needle sub-
unit proteins are related to secretory regulation and multiple
YscFmutants demonstrate a constitutive-secretion phenotype
(Torruellas et al., 2005; Davis andMecsas, 2007). A dominant-
negative YscF mutant, L54V, blocks secretion of parental YscF
and Yop effectors and fails to assemble the injectisome (Davis
et al., 2010). Mutations in the Shigella needle protein MixH,
lead to constitutive secretion of effectors, some of which
are also not inducible (Kenjale et al., 2005). The conserved
tertiary structure of both needle subunits and tip proteins
is coiled-coil formed by two α-helices, suggesting a simi-
lar mechanism of oligomeric assembly (Kenjale et al., 2005;
Torruellas et al., 2005; Blocker et al., 2008). Biophysical analy-
ses of common α-helical coiled-coil structures demonstrated
that an allosteric potential in this type of structure induces
conformational ampliﬁcation involved in mechanotransduc-
tion. In other words, these proteins appear to function as a
nanoswitch (Yogurtcu et al., 2010). Thus, the environmental
signals sensed by the tip complex may be ampliﬁed and trans-
mitted to the cytoplasmic side through the needle proteins by
conformational changes in coiled-coil structures.
(3) Inner membrane proteins: An inner membrane component
in Yersinia, YscU, recognizes translocators for secretion and is
involved in substrate switching. Amino acid substitutions at
speciﬁc residues of YscU fail to autocleave the cytoplasmic C-
terminal domain and abolish export of translocator proteins
LcrV, YopB, and YopD but not Yop effectors (Sorg et al., 2007;
Riordan and Schneewind, 2008).
(4) The ATPase complex in the basal body and cytoplasmic
chaperones: The basal body consists of the outer and inner
rings connected by a neck domain and the ATPase complex
(Figure 1; reviewed in Galan and Wolf-Watz, 2006). Salmo-
nella enterica ATPase, InvC, has a critical role in substrate
recognition and release of cognate chaperones (Akeda and
Galan, 2005). T3SS-speciﬁc chaperones are classiﬁed based
on their cognate interacting partners, effectors, transloca-
tors, and needle proteins (Stebbins and Galan, 2003; Cornelis,
2006). Prior to export, chaperones interact with their secreted
protein substrates to target this sub-assemblage to theATPase-
sorting complex associatedwith the basal body.At this speciﬁc
locale, the effector protein is unfolded, dissociated from the
effector-chaperone complex, and then presented to the sort-
ing complex (Boyd et al., 2000; Luo et al., 2001; Birtalan et al.,
2002; Galan and Wolf-Watz, 2006; Lara-Tejero et al., 2011).
An alternative interface of the effector–chaperone complex
induced by conformational changes may act as a recogni-
tion signal for the controlled export of effectors (Stebbins
and Galan, 2003). In addition, the ATPase provides proton
motive force for export of substrates (Eichelberg et al., 1994;
Wilharm et al., 2004). Tip protein-speciﬁc chaperones PcrG
and LcrG for PcrV and LcrV, respectively, possess a regu-
latory function in T3 protein secretion in the presence of
calcium (Nilles et al., 1997; Matson and Nilles, 2001; McCaw
et al., 2002; Sundin et al., 2004; Rietsch et al., 2005). In
Yersinia, a deletion of lcrG leads to premature release of
Yop proteins (DeBord et al., 2001). In the Pseudomonas sys-
tem, the interaction between PcrV and its cognate chaper-
one PcrG facilitates the export of PcrV despite the absence
of an inﬂuence on the secretory regulation of effectors
(Lee et al., 2010).
(5) Cytoplasmic regulators: an intrabacterial regulator YopN in
Yersinia complexes with the co-regulatory protein TyeA to
control the entry of secreted proteins to the basal body (Fors-
berg et al., 1991; Iriarte et al., 1998; Ferracci et al., 2005;
Schubot et al., 2005). MxiC, an ortholog of YopN in Shigella,
interacts with the Spa47 ATPase (Botteaux et al., 2009). A
knockout mutant of mxiC constitutively secretes effectors
but the secretion of translocator IpaC is weak and delayed
upon type III induction (Botteaux et al., 2009; Martinez-
Argudo and Blocker, 2010). Another cytoplasmic regulator
is a molecular ruler or timer, YscP in Yersinia and Spa32 in
Shigella. These molecules determine the needle length and are
also involved in the control of substrate speciﬁcity switching
(Journet et al., 2003; Agrain et al., 2005).
(6) In both Pseudomonas andYersinia systems, translocated effec-
tor proteins ExoS and YopE play some role in a negative
regulatory loop. After delivery of ExoS and YopE into the
host cytosol, additional cycles of effector translocation into
the same host cell are blocked in a feedback fashion (Aili et al.,
2008;Cisz et al., 2008;Urbanowski andYahr,2008). Themech-
anisms of regulation or feedback signal transduction have not
been deﬁned.
TRANSLOCON ASSEMBLY AND BRIDGING TO THE NEEDLE STRUCTURE
Activation of the T3 secretory activity initiates the assembly of a
translocation complex, called a translocon, in eukaryotic mem-
branes (Figure 1). P. aeruginosa requires the products of the
pcrGVHpopBD operon to form the translocon (Frank, 1997; Yahr
et al., 1997; Frithz-Lindsten et al., 1998). PcrV, PopB, and PopD
are classiﬁed as translocators or translocases necessary to form
the translocon structure in eukaryotic membranes (Lee et al.,
2000; Schoehn et al., 2003; Goure et al., 2004; Caroline et al.,
2008). PopB and PopD are hydrophobic translocators that insert
into membrane lipids while a hydrophilic translocator, PcrV, is
required for assembly and insertion of the functional PopB/PopD
translocon into host membranes (Frithz-Lindsten et al., 1998;
Goure et al., 2004, 2005). The translocon assembly is necessary for
contact-dependent lysis of erythrocytes and the one-step delivery
of effector proteins into the host cytosolic compartment (Hakans-
son et al., 1996; Lee et al., 2000; Schoehn et al., 2003; Goure et al.,
2004; Cornelis, 2006; Galan and Wolf-Watz, 2006; Blocker et al.,
2008; Caroline et al., 2008). Also, contact-dependent activation
of T3SS requires translocon proteins PopB and PopD as well as
host cell integrity (Cisz et al., 2008). Using a Yersinia co-infection
system, YopB, YopD, and LcrV are sufﬁcient for channel forma-
tion when these proteins are expressed and secreted by the same
bacterium (Marenne et al., 2003).
The formation of translocon channels is assessed by the
release of hemoglobins from erythrocytes (Blocker et al., 1999;
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Neyt and Cornelis, 1999; Goure et al., 2005). Pore formation in
eukaryotic cells can be identiﬁed by infection with effectorless
strains of T3SS-competent bacteria (Frithz-Lindsten et al., 1998;
Viboud and Bliska, 2001; Marenne et al., 2003; Roy et al., 2004;
Sato et al., 2011). Even in the absence of known effector proteins,
expression of PcrV and other type III components leads to cell
damage (Roy et al., 2004; El Solh et al., 2008). V-protein deletion
strains are non-cytotoxic andnon-hemolytic due to the inability to
assemble and insert the translocon in the host membranes (Sarker
et al., 1998; Sawa et al., 1999; Goure et al., 2004; Sato et al., 2011).
Complementation with a wild-type copy of pcrV restores cytotox-
icity and hemolytic activity (Sawa et al., 1999; Goure et al., 2004;
Sato et al., 2011). These results suggest that PcrV is involved in the
mechanical control of translocon formation and insertion in lipid
bilayers. It is believed that V-proteins act as a platform for assem-
bly and insertion of translocons (Sarker et al., 1998; Goure et al.,
2004; Broz et al., 2007). V-proteins may have a chaperone func-
tion for translocon assembly and possibly for self-oligomerization
(Goure et al., 2005). The Inv-Mxi-Spa family tip proteins possess
a chaperone domain in the N-terminus (reviewed in Blocker et al.,
2008). It has also been shown that the C-terminal α-helix of BipD
is involved in contacts with translocon proteins (Erskine et al.,
2006).
In cell culture systems, effector proteins are translocated into
the host cytoplasm in a polarized or vectorial manner (Rosqvist
et al., 1994; Sory and Cornelis, 1994; Persson et al., 1995; Vallis
et al., 1999a,b). It has been suggested that the tip complex forms
a physical bridge between the needle and translocon assembled
within the host membrane (Knutton et al., 1998; Nilles et al., 1998;
Daniell et al., 2001; Sato et al., 2011).The leakage of effector pro-
teins in the cell culture medium is minimum and rarely detectable
during infection in vitro (Vallis et al., 1999a,b; Sundin et al., 2004;
Sato et al., 2011).
IMMUNIZATION AND THERAPEUTICS TARGETING T3SS
LcrV: A PROTECTIVE EPITOPE OF YERSINIA AND DETERMINANT FOR
EVASION OF HOST INNATE IMMUNITY
LcrV was ﬁrst identiﬁed as an antigenic factor of Y. pestis and
named “V-antigen” by Burrows and Bacon (1956). Active immu-
nization with V-antigen protects against pneumonic and bubonic
plague in mice (Lawton et al., 1963; Leary et al., 1995; Anderson
et al., 1996). Polyclonal antibodies for LcrV provide passive pro-
tection against infection with Y. pestis and Y. pseudotuberculosis
(Une and Brubaker, 1984; Motin et al., 1994). LcrV is located at
the tip of needles and surface exposed on bacteria so that anti-LcrV
antibodies can inhibit the translocon assembly, causing a failure of
effector delivery into target cells (Fields et al.,1999;Pettersson et al.,
1999;Mueller et al., 2005). LcrVpossesses conformational epitopes
reported by several groups (Hill et al., 1997; Vernazza et al., 2009;
Quenee et al., 2010). In addition to conformational epitopes, a lin-
ear epitope was identiﬁed in LcrV (amino acid residues 195–225;
Figure 2; Quenee et al., 2010). Several laboratories developed LcrV
subunit vaccines (rV) alone or in combination with other Y. pestis
proteins, such as the fraction 1 pilus capsular antigen or rF1,which
are currently in clinical trials (Powell et al., 2005;Williamson et al.,
2005; Quenee and Schneewind, 2009).
Another biological function of LcrV is blocking host inﬂamma-
tory responses and triggering immunosuppression by the release
of IL-10 (Nakajima et al., 1995; Nedialkov et al., 1997; Sing et al.,
2002a; Brubaker, 2003; Overheim et al., 2005). IL-10 release was
ampliﬁed in a TLR2/TLR6 and CD14-dependent manner, sug-
gesting that Yersinia evades the host innate immune response by
exploiting innate pattern recognitionmolecules (Sing et al., 2002b,
2005; Depaolo et al., 2008). Additionally, LcrV inhibits the release
of proinﬂammatory cytokines, IFN-γ and TNF-α (Nakajima and
Brubaker, 1993; Nakajima et al., 1995). Therapeutically, the ability
of LcrV to suppress IFN-γ and TNF-α release was utilized to post-
pone the inﬂammatory response in mouse skin allograft models
(Motin et al., 1997). A deletion of residues 271–300 in LcrV (the
position is indicated in the structural model in Figure 2) elimi-
nated the immunomodulatory responses and this variant protein
has been developed to the rV10 subunit vaccine (Overheim et al.,
2005). Active immunization with rV10 alone or a combination
with rF1 protects cynomolgus macaques from pneumonic plague,
and the antibodies from macaques provide protection against
bubonic plaque in mice (Cornelius et al., 2008). Active immu-
nization with rV10 was also protective in rats and mice (DeBord
et al., 2006; Anderson et al., 2009). The rV10 vaccine is undergoing
the preclinical efﬁcacy study (Cornelius et al., 2008) along with the
FDA pre-investigational new drug authorization review (Quenee
and Schneewind, 2009).
PcrV: A PROTECTIVE EPITOPE OF PSEUDOMONAS
Among three translocator proteins, only PcrV is a potent protec-
tive antigen against T3SS-mediated Pseudomonas infection (Sawa
et al., 1999; Holder et al., 2001; Frank et al., 2002). Active immu-
nization with recombinant PcrV protects mice from lethal infec-
tion even under induced-leukocytopenia or immunosuppression
induced by a burn injury (Sawa et al., 1999; Holder et al., 2001;
Moriyama et al., 2009). Passive immunization with polyclonal
antisera, afﬁnity-puriﬁed antibodies, or F(ab′)2 were effective
against cellular intoxication, lung injury, bacteremia, and sepsis
in animal models (Sawa et al., 1999; Shime et al., 2001; Frank et al.,
2002; Neely et al., 2005; Imamura et al., 2007; Baer et al., 2009).
Polyclonal anti-PcrV antibodies block T3SS-mediated hemolysis
of erythrocytes and cytotoxicity of macrophages in vitro (Goure
et al., 2005; Sato et al., 2011) and reduce inﬂammatory response
and lung injury in infected BALB/c mice (Sawa et al., 1999). In
addition to the inhibition of the delivery of effector proteins, anti-
PcrV antibodies decrease anti-phagocytic effects mediated by host
cells (Sawa et al., 1999).
More than 80 monoclonal stable cell lines were screened by
in vitro and in vivo assays to identify an antibody or combination
of antibodies that neutralize the cytotoxic effect of P. aeruginosa
infection (Frank et al., 2002). Mab166 possesses this property and
was subsequently developed to a humanized single-chain antibody
for immunotherapy. TheF(ab′)2 single-chain antibody conjugated
with polyethylene glycol was initially produced by InterMune
(Frank et al., 2002; Baer et al., 2009; Moriyama et al., 2009) and
subjected to a proprietary afﬁnity maturation procedure by Kalo-
bios to produce KB001. Phase 1 and 1/2 clinical studies of KB001
have been completed in mechanically ventilated ICU patients and
cystic ﬁbrosis patients. The results of clinical trials indicated the
Frontiers in Microbiology | Cellular and Infection Microbiology July 2011 | Volume 2 | Article 142 | 6
Sato and Frank Type III secretion needle-tip proteins
reduction in the number of inﬂammatory cells and markers and
decreased pneumonia events (KaloBios website2).
The protective epitope in PcrV is conformational and located
within a region between amino acids 144 and 257 (deletion map-
ping) or between 158 and 217 as determined by phage display
(Frank et al., 2002). Only a conformational epitope has been iden-
tiﬁed in PcrV at this time (Frank et al., 2002). Mab166 is reactive
to the epitope located in the globular region between the central
and C-terminal helices (Figure 2). The location of the epitope in
the PcrV-structure models overlaps the regions identiﬁed as the
linear and conformational epitopes of LcrV (Vernazza et al., 2009;
Quenee et al., 2010). There is no indication of PcrV-mediated
immunomodulatory effectswhile LcrV increases IL-10production
anddecreases the release of proinﬂammatory cytokines, IFN-γ and
TNF-α (Nakajima and Brubaker, 1993; Nakajima et al., 1995; Sing
et al., 2002a). PcrV has little homology to TLR2-binding motifs
located in LcrV, which are responsible for IL-10 induction (Sing
et al., 2005; Abramov et al., 2007). In contrast to LcrV, PcrV does
not colocalize with TLR2 (Sing et al., 2002b; Overheim et al.,
2005). T3SS-competent P. aeruginosa strains, but not the deletion
mutants of pcrV or other translocator genes, recruit neutrophils to
the lung, triggering inﬂammatory responses (Wangdi et al., 2010).
Pseudomonas aeruginosa is intrinsically resistant to a broad
range of antibiotics. A high rate of ventilator-associated pneu-
monia and mortality in patients is caused by P. aeruginosa (Rello
et al., 1993). PcrV is expressed in most of the type III positive
clinical isolates from patients with acute lower respiratory tract
infection and systemic infection (Roy-Burman et al., 2001). Infec-
tion with PcrV-positive isolates results in high mortality rate even
in the absence of cytotoxin ExoU or ExoS (Roy-Burman et al.,
2001; El Solh et al., 2008). These data indicate that there might be
advantages to the use of PcrV as a therapeutic target. The neutral-
ization of PcrV likely confers little selective pressure to bacteria for
their development to a resistant phenotype as compared to selec-
tion of resistance through the use of current antibiotic therapies.
Thus, passive or active immunization may be useful in combina-
tion therapies against intrinsically resistant P. aeruginosa isolates
(El Solh and Alhajhusain, 2009).
POSSIBLE THERAPEUTICS FOR OTHER TYPE III TARGETS
Immunotherapies targeting a needle-tip protein have been also
studied for other type III-positive bacteria. Antibodies recogniz-
ing the N-terminus of IpaD neutralize the hemolytic activity of
S. ﬂexneri (Espina et al., 2006). Antibodies against SipD (SPI-1)
protect epithelial cells from invasion by S. enterica serovar Enteri-
tidis (Desin et al., 2010). In contrast, active immunization of mice
with recombinant BipD is not protective against experimental
melioidosis (Druar et al., 2008). CT584 does not induce antibody
responses in humans infected with C. trachomatis (Wang et al.,
2010a). It will be interesting to see the efﬁcacy of a multivalent
vaccine based on tip proteins IpaD, BipD, SipD, LcrV, and PcrV,
which is in the initial stages of development (Markham et al.,
2010). For ﬁlamentous-tip protein family, anti-EspA antibodies
inhibit cytoskeletal changes in host cells in vitro (La Ragione et al.,
2http://www.kalobios.com/kb_pipeline_001.php
2006). One monoclonal antibody speciﬁc to a linear epitope of
EspA was protective against EHEC infection (Yu et al., 2011).
Polyclonal sera reactive to Bsp22 protects mice against Bordetella
infection (Medhekar et al., 2009). Interestingly, the needle protein
YscF of Y. pestis, another surface-exposed type III protein, induces
signiﬁcant antibody responses and protective effects in mice upon
active immunization (Matson et al., 2005).
Another aspect of immunotherapy studies concerns improve-
ment in delivery methods and adjuvants. For example, various
and effective delivery methods of vaccines against Yersinia infec-
tion include liposomal delivery of epitopes or virus-based delivery
of vaccines (Chattopadhyay et al., 2008; Heurtault et al., 2009;
Bhattacharya et al., 2010; Van Blarcom et al., 2010). Also, whole-
cell vaccines, either killed or live and attenuated have been well
studied (Bumann et al., 2010; Kamei et al., 2011 and reviewed in
Quenee and Schneewind, 2009).
Small molecule inhibitors targeting T3SS have been pursued
for the development of novel therapeutics. Inhibitors targeting the
enzymatic activity of type III effector proteins, ExoU and ExoS, are
effective in vitro (Lee et al., 2007; Arnoldo et al., 2008). Inhibitors
speciﬁc to a Yersinia transcription factor, LcrF (VirF), were effec-
tive againstY. pseudotuberculosis-mediated cytotoxicity in vitro and
bacterial burden in the lungs in mice of pneumonia, increasing
their survival (Garrity-Ryan et al., 2010). Moreover, numerous
small molecules have been screened for antivirulence inhibitors
targeting the T3SS in several genera of bacteria (Veenendaal et al.,
2009; Baron, 2010).
CONCLUDING REMARKS
The T3SS is a potent part of the virulence machinery expressed by
P. aeruginosa andmultiple Gram-negative pathogens. Assembly of
type III components and subsequent execution of this intoxication
system are intricately regulated and coordinated at multiple levels.
Having a comprehensive understanding of these systems as well
as working out the mechanistic steps of each stage in the process
will give investigators a clue toward the development of novel
therapeutics. These therapeutics could target the assembly of the
injectisome, the sensing of the microenvironment followed by sig-
nal transduction, transcriptional activation, translocon formation
in hostmembranes, and effector delivery into the host cytoplasmic
compartment. The PcrV tip complex is located at the distal end of
the needle and responsible for several important functions. pcrV -
deletion strains are unable to intoxicate host target cells due to a
failure in the formation of the translocon channel in host plasma
membranes. Thus, the structural and functionalmechanismof the
tip proteins and translocon proteins is particularly relevant to the
design of vaccines and therapeutics targeted to neutralize T3SS-
mediated intoxication (Motin et al., 1994; Hill et al., 1997; Sawa
et al., 1999; Brubaker, 2003; Baer et al., 2009).
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